Core Insights - Phio Pharmaceuticals Corp. has received FDA acceptance for a nonclinical protocol study design, marking a significant advancement in the drug development pathway for PH-762, a treatment for skin cancer [1][3] - The company plans to commence a toxicology study in the first quarter of 2026, which is a prerequisite for initiating human pivotal trials [1] - Positive interim results from an ongoing Phase 1b clinical trial of PH-762 show promising safety and efficacy, with no dose-limiting toxicities reported [2] Group 1: Drug Development Progress - The FDA has accepted the nonclinical protocol study design for PH-762, allowing the company to move forward with necessary studies [1][3] - A toxicology study is set to begin in Q1 2026, which is essential for progressing to human trials [1] - The company is also working on delivering a commercially viable drug product by 2026, adhering to FDA's Good Manufacturing Practices [1][3] Group 2: Clinical Trial Results - The Phase 1b trial has treated 18 patients with cutaneous carcinomas, showing a cumulative pathologic response in 16 patients, including six with complete response (100% clearance) [2] - No patients exhibited clinical progression of disease during the trial, and PH-762 was well tolerated across all dose cohorts [2] - The trial results indicate a promising safety profile, with no dose-limiting toxicities or clinically relevant adverse effects reported [2] Group 3: Company Overview - Phio Pharmaceuticals Corp. is focused on developing therapeutics using its proprietary INTASYL® gene silencing technology, particularly in the field of immuno-oncology [4] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, positioning it as a potential non-surgical treatment option [4] - The ongoing Phase 1b trial is evaluating PH-762 for cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4]

Core Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][4] - The company will present updates on its ongoing Phase 1b clinical trial for its lead product candidate PH-762 at the Life Sciences Future Conference on September 25-26, 2025 [1][2] Company Overview - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is advancing its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [4] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] - The ongoing Phase 1b trial (NCT 06014086) is evaluating PH-762 as a potential non-surgical treatment for skin cancers [4] Conference Details - The presentation by Mr. Robert Bitterman, President and CEO, will include updates on the Phase 1b clinical trial and future strategies for the PH-762 development program [2] - The Life Sciences Future Conference will take place at the Sheraton Valley Forge Hotel in King of Prussia, PA, on September 25-26, 2025 [3]

Core Viewpoint - iTeos Therapeutics, Inc. intends to wind down its operations as part of a strategic review aimed at maximizing shareholder value through potential asset sales and leveraging its cash balance [2][3]. Group 1: Company Operations - The Board of Directors has decided to cease clinical and operational activities following a comprehensive assessment of the company's development pipeline and financial position [3]. - The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders [2][3]. Group 2: Company Background - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics, leveraging its expertise in tumor immunology [4].